Literature DB >> 2308602

Small-bowel length and the dose of cyclosporine in children after liver transplantation.

P F Whitington1, J C Emond, S H Whitington, C E Broelsch, A L Baker.   

Abstract

Children, particularly infants, require large oral doses of cyclosporine to achieve immunosuppression after liver transplantation. In 53 children who had received liver transplants, we examined the relation of height, weight, residual small-bowel length, and (in 17 children) the terminal plasma clearance rate of cyclosporine to the dose of cyclosporine required to achieve blood levels of 200 ng per milliliter. The required intravenous dose of cyclosporine (expressed as milligrams per day) increased steeply as body size and bowel length increased, whereas the required oral dose declined with increasing bowel length. When expressed as milligrams per square meter of body-surface area per day, the required intravenous dose did not change with body size, but the required oral dose declined with increasing body size. Small-bowel length correlated closely and inversely with the log of the oral dose of cyclosporine (r = -0.77, P = 0.0001). The rate of clearance was also related to the log of the oral dose (r = 0.57, P = 0.017) but was independent of age and size. Multiple regression analyses that included height and weight showed that only small-bowel length and the rate of clearance from plasma were independently related to the required oral dose of cyclosporine. We concluded that the length of the small bowel is the chief determinant of the required dose of orally administered cyclosporine in children after liver transplantation. Children and infants require large oral doses of cyclosporine because of the limited absorptive surface area of their intestines.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2308602     DOI: 10.1056/NEJM199003153221105

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  19 in total

Review 1.  Optimisation of immunosuppressive therapy using pharmacokinetic principles.

Authors:  J Grevel
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

2.  Enhancement of the oral absorption of cyclosporin in man.

Authors:  J Drewe; R Meier; J Vonderscher; D Kiss; U Posanski; T Kissel; K Gyr
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

3.  Higher plasma bilirubin predicts veno-occlusive disease in early childhood undergoing hematopoietic stem cell transplantation with cyclosporine.

Authors:  Kwi Suk Kim; Aree Moon; Hyoung Jin Kang; Hee Young Shin; Young Hee Choi; Hyang Sook Kim; Sang Geon Kim
Journal:  World J Transplant       Date:  2016-06-24

Review 4.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 5.  Cyclosporin pharmacokinetics in paediatric transplant recipients.

Authors:  G F Cooney; K Habucky; K Hoppu
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

6.  Age effect on whole blood cyclosporine concentrations following oral administration in children with nephrotic syndrome.

Authors:  Katsumi Ushijima; Osamu Uemura; Takuji Yamada
Journal:  Eur J Pediatr       Date:  2011-11-26       Impact factor: 3.183

7.  The absorption site of cyclosporin in the human gastrointestinal tract.

Authors:  J Drewe; C Beglinger; T Kissel
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

Review 8.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

9.  Liver transplantation in children from living related donors. Surgical techniques and results.

Authors:  C E Broelsch; P F Whitington; J C Emond; T G Heffron; J R Thistlethwaite; L Stevens; J Piper; S H Whitington; J L Lichtor
Journal:  Ann Surg       Date:  1991-10       Impact factor: 12.969

10.  Evidence for pre-hepatic metabolism of oral cyclosporine in children.

Authors:  K Hoppu; O Koskimies; C Holmberg; E L Hirvisalo
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.